• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Changes to MEOS and Barriers to Entry


As terms for Monthly Enhanced Oncology Services (MEOS) payments are set to change under the EOM, panelists worry that the barriers to entry to value-based care will be too high for practices that did not participate in the OCM.

Moderator Stuart Staggs, MSIE, senior director, strategic programs, The US Oncology Network, takes the discussion where everyone wants it to go: MEOS payments. What will lower payments—from $160 per patient per month to $70 for most patients, and $100 for those dually eligible for Medicare and Medicaid, mean for practices? Fred Divers, MD, chief medical officer, American Oncology Network and medical oncologist, Genesis Cancer and Blood Institute of Arkansas, highlights the lack of a copayment for patients as a plus of the EOM, and says it’s good there is extra revenue tied to caring for the Medicaid population. But Divers and Stephen Schleicher, MD, MBA, chief medical officer, Tennessee Oncology, both express concern about the barrier to entry issue for practices that most need to try value-based care. Kashyap Patel, MD, CEO, Carolina Blood and Cancer Care Associates and president, Community Oncology Alliance, says that CMMI would benefit from broader thinking about rewarding practices for attending to the global cost of care. Divers also notes the effect that inflation has had on practices, as the cost of supplies has increased.

Related Videos
Video 2 - "Payer Needs and Strategies for Evaluating and Covering PDTs"
Video 1 - "Differentiating PDTs from Wellness Apps and Evaluating Efficacy"
Video 4 - "Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer"
Video 3 - "The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer"
"Integrating New PAH Therapies into Clinical Practice"
Julie Patterson, PharmD, PhD
"Clinical Evidence for Emerging PAH Therapies"
Neil Goldfarb, CEO, Greater Philadelphia Business Coalition on Health
Screenshot of Fran Gregory, PharmD, MBA, during a video interview
Video 13 - "Individualized Therapy for Specific Infections Associated with Bronchiectasis"
Related Content
© 2024 MJH Life Sciences
All rights reserved.